Psyence Biomedical Ltd. Warrant (PBMWW)

Psyence BioMed made a $3.5 million follow-on investment in PsyLabs, a leading producer of psychedelic pharmaceutical ingredients, to secure a sustainable and ethical supply chain for its clinical research programs in mental health therapies.

U.S. stock futures declined ahead of the 'Triple Witching' hour, with the market expected to see the expiry of about $6.6 trillion options. Analysts have mixed views on the market's recovery by the end of the year.